Free Newsletter
CSL sees first-half profit dip
Blood products group CSL cited foreign exchange losses, falling royalties from a drop in sales of its cervical cancer and swine-flu vaccines for a $117 million dive in first-half profit. The company's net result fell to $500.21 million, down from $617.39 million last year when windfall sales of Panvax, the Australian developed swine flu treatment, boosted its bottom line. News
More stories about CSL
Comments
Post new comment
Paid Research Reports
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline
- Innovative Drug Discovery in Emerging Markets
- Market Opportunities for Supergenerics
- The Future of In Vitro and In Vivo Diagnostic Integration
More Research Reports >>
SHARE
WITH: